Actinium Pharmaceuticals to Present at the 3rd Annual Targeted Radiopharmaceuticals Summit US
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) will present at the 3rd Annual Targeted Radiopharmaceuticals Summit US in San Diego from July 30 - August 1, 2024. The presentation, titled 'Overcoming Adverse Cytogenetics, TP53, Other Mutations & Treatment Resistant Disease in Relapsed/Refractory AML Using Antibody Radiation Conjugates,' will take place on July 31, 2024.
The presentation will highlight:
- Iomab-B, a CD45 I-131 ARC, enabling bone marrow transplant in otherwise ineligible patients
- Actimab-A, a CD33 Ac-225 ARC, demonstrating strong anti-leukemic activity
- Responses in heavily pretreated patients, including those with prior venetoclax treatment or TP53-mutated disease
- Preclinical data showing benefits of combining Actimab-A with targeted therapies like FLT3 inhibitors
Both Iomab-B and Actimab-A are the only clinical stage antibody radiation conjugates in development for acute myeloid leukemia patients.
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) presenterà al 3° Annual Targeted Radiopharmaceuticals Summit US a San Diego dal 30 luglio al 1° agosto 2024. La presentazione, intitolata 'Superare la citogenetica avversa, le mutazioni TP53 e altre mutazioni, e la malattia resistente al trattamento nella leucemia mieloide acuta recidivante/rifrangente utilizzando coniugati di radiazioni ad anticorpi,' si svolgerà il 31 luglio 2024.
La presentazione metterà in evidenza:
- Iomab-B, un ARC I-131 CD45, che consente il trapianto di midollo osseo in pazienti diversamente non idonei
- Actimab-A, un ARC Ac-225 CD33, che dimostra una forte attività anti-leucemica
- Risposte in pazienti pesantemente pretrattati, inclusi quelli con trattamento precedente con venetoclax o malattia mutata TP53
- Dati preclinici che mostrano i vantaggi della combinazione di Actimab-A con terapie mirate come gli inibitori di FLT3
Sia Iomab-B che Actimab-A sono gli unici coniugati di radiazione ad anticorpi in fase clinica in sviluppo per pazienti con leucemia mieloide acuta.
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) presentará en la 3ª Cumbre Anual de Radiotecnologías Dirigidas en EE. UU. en San Diego del 30 de julio al 1 de agosto de 2024. La presentación, titulada 'Superando la Citogenética Adversa, TP53, Otras Mutaciones y Enfermedad Resistente al Tratamiento en Leucemia Mieloide Aguda Recaída/Refractaria Usando Conjugados de Radiación Anticuerpo,' se llevará a cabo el 31 de julio de 2024.
La presentación destacará:
- Iomab-B, un ARC de I-131 CD45, que permite el trasplante de médula ósea en pacientes que de otro modo serían inelegibles
- Actimab-A, un ARC de Ac-225 CD33, que demuestra una fuerte actividad anti-leucémica
- Respuestas en pacientes con tratamientos previos intensivos, incluidos aquellos con tratamiento anterior con venetoclax o enfermedad mutada TP53
- Datos preclínicos que muestran los beneficios de combinar Actimab-A con terapias dirigidas como los inhibidores de FLT3
Tanto Iomab-B como Actimab-A son los únicos conjugados de radiación con anticuerpos en etapa clínica en desarrollo para pacientes con leucemia mieloide aguda.
액티니움 제약(Actinium Pharmaceuticals) (NYSE AMERICAN: ATNM)은 2024년 7월 30일부터 8월 1일까지 샌디에고에서 개최되는 제3회 연례 표적 방사성 의약품 정상 회담(Targeted Radiopharmaceuticals Summit US)에서 발표할 예정입니다. 발표 제목은 '재발/난치성 급성 골수성 백혈병에서 항체 방사선 접합체를 사용하여 불리한 세포유전학, TP53, 기타 돌연변이 및 치료 저항 질환 극복하기,'로 2024년 7월 31일에 진행됩니다.
발표에서는 다음과 같은 내용이 강조될 것입니다:
- Iomab-B, CD45 I-131 ARC로, 다른 경우에 비해 이식이 불가능한 환자들에게 골수 이식을 가능하게 합니다
- Actimab-A, CD33 Ac-225 ARC로, 강력한 항백혈병 활성을 입증합니다
- 베네토클락스 치료 또는 TP53 돌연변이가 있는 환자를 포함하여 중증으로 사전 치료를 받은 환자에서의 반응
- Actimab-A와 FLT3 억제제와 같은 표적 치료를 병합할 때의 이점을 보여주는 전임상 데이터
Iomab-B와 Actimab-A는 급성 골수성 백혈병 환자를 위한 개발 중인 유일한 임상 단계 항체 방사선 접합체입니다.
Actinium Pharmaceuticals (NYSE AMERICAN : ATNM) présentera lors du 3e Sommet Annuel des Radiopharmaceutiques Ciblés aux États-Unis à San Diego, du 30 juillet au 1er août 2024. La présentation, intitulée 'Surmonter la Cytogénétique Défavorable, TP53, D'autres Mutations et Maladie Résistante au Traitement dans la LMA Récidivante/Réfractaire Utilisant des Conjugués Anticorps-Radiation,' aura lieu le 31 juillet 2024.
La présentation mettra en avant :
- Iomab-B, un ARC de CD45 I-131, permettant la transplantation de moelle osseuse chez des patients autrement non éligibles
- Actimab-A, un ARC de CD33 Ac-225, montrant une forte activité anti-leucémique
- Réponses chez des patients lourdement prétraités, y compris ceux ayant reçu un traitement préalable avec le venetoclax ou présentant une maladie mutée TP53
- Données précliniques montrant les avantages de la combinaison d'Actimab-A avec des thérapies ciblées telles que les inhibiteurs de FLT3
Tant Iomab-B qu'Actimab-A sont les seuls conjugués anticorps-radiation en phase clinique en développement pour les patients atteints de leucémie myéloïde aiguë.
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) wird vom 30. Juli bis 1. August 2024 beim 3. Annual Targeted Radiopharmaceuticals Summit US in San Diego präsentieren. Die Präsentation mit dem Titel 'Überwindung von nachteiliger Zytogenetik, TP53, anderen Mutationen und behandlungsresistenter Erkrankung bei rezidivierter/refraktärer AML unter Verwendung von Antikörper-Radioaktiven Konjugaten,' findet am 31. Juli 2024 statt.
In der Präsentation werden folgende Punkte hervorgehoben:
- Iomab-B, ein CD45 I-131 ARC, das eine Knochenmarktransplantation bei sonst nicht geeigneten Patienten ermöglicht
- Actimab-A, ein CD33 Ac-225 ARC, das eine starke antileukämische Aktivität zeigt
- Reaktionen bei stark vorbehandelten Patienten, einschließlich solcher mit vorheriger Venetoclax-Behandlung oder TP53-mutierter Erkrankung
- Präklinische Daten, die die Vorteile der Kombination von Actimab-A mit zielgerichteten Therapien wie FLT3-Inhibitoren zeigen
Sowohl Iomab-B als auch Actimab-A sind die einzigen antikörperbasierten Radioaktiven Konjugate in der klinischen Entwicklungsphase für Patienten mit akuter myeloischer Leukämie.
- None.
- None.
- Presentation to highlight positive outcomes of Iomab-B led bone marrow transplant in difficult to treat TP53 patients and the mutation-agnostic mechanism of Actimab-A for patients with relapsed or refractory acute myeloid leukemia
- Iomab-B and Actimab-A represent the only clinical stage antibody radiation conjugates in development for patients with acute myeloid leukemia
- Exploring Iomab-B, a CD45 I-131 ARC, to enable bone marrow transplant (BMT) in otherwise ineligible patients, while Actimab-A, a CD33 Ac-225 ARC, demonstrates strong anti-leukemic activity
- Outlining responses in heavily pretreated patients for both Iomab-B and Actimab-A, including prior venetoclax treatment or TP53-mutated disease, to demonstrate how targeted radiotherapies offer broad therapeutic potential as backbone regimens
- Revealing preclinical data to further show the benefits of combining Actimab-A with targeted therapies, such as FLT3 inhibitors, to enhance anti-tumor response
For more information about the Targeted Radiopharmaceutical Summit and the conference agenda, please visit https://targeted-radiopharma-us.com/.
About Actinium Pharmaceuticals, Inc.
Actinium develops targeted radiotherapies to meaningfully improve survival for people who have failed existing oncology therapies. Advanced pipeline candidates Iomab-B (pre-BLA & MAA (EU)), an induction and conditioning agent prior to bone marrow transplant, and Actimab-A (Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute), a therapeutic agent, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. Actinium plans to advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. Actinium holds more than 230 patents and patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron.
For more information, please visit: https://www.actiniumpharma.com/
Contact:
investorrelations@actiniumpharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-to-present-at-the-3rd-annual-targeted-radiopharmaceuticals-summit-us-302206068.html
SOURCE Actinium Pharmaceuticals, Inc.
FAQ
What is Actinium Pharmaceuticals presenting at the 3rd Annual Targeted Radiopharmaceuticals Summit US?
What are Iomab-B and Actimab-A, and how do they differ?
How effective are Actinium's ARCs in treating patients with TP53 mutations?
What preclinical data will Actinium Pharmaceuticals (ATNM) reveal at the summit?
